Imaging AI in Virginia

RIVANNA Medical develops AI-automated clinical decision support platforms for spinal needle intervention guidance and musculoskeletal diagnostics at the point of care. The company's proprietary technology combines deep learning algorithms trained on proprietary clinical datasets with advanced 3D ultrasound transducer technology to reduce operator variability and accelerate clinical decision-making in emergency medicine and anesthesia applications. Core product offerings include the Accuro 3S Needle Guide Kit (FDA 510(k) cleared as of December 2025) for neuraxial anesthesia procedures, and an AI-powered fracture triage platform for emergency department point-of-care imaging. Both products leverage RIVANNA's unified AI imaging architecture, which integrates SafeTrack™ needle tracking technology, Dual-Array™ multi-angle probe technology, and 3D volumetric imaging capabilities. The platforms feature portable bedside deployment, automated acquisition with minimal training dependency, real-time needle tip positioning overlays, and seamless EMR and DICOM integration with cloud connectivity for fleet analytics. The company addresses critical healthcare delivery gaps: ~70% of extremity fracture cases in emergency departments are rule-outs, yet patients wait hours for radiology confirmation; neuraxial anesthesia procedures relying on landmark palpation exhibit 38% first-attempt failure rates in challenging anatomies. RIVANNA's platforms target a combined total addressable market of $3.4B+ across neuraxial guidance ($1.9B) and fracture care ($1.5B). Validation includes NIH federal support, 8 clinical sites with 1,200+ enrolled subjects, peer-reviewed publication in Journal of Emergency Medicine (2026), and $3 million CDMRP grant award for military-optimized ultrasound guidance systems. The company holds 48 global patents and patents pending. Regulatory pathway includes FDA 510(k) clearance for Accuro 3S consumables, with SafeTrack™ needle tracking and fracture platform submissions pending. ICD-10-PCS coding is pending; CPT pathway validation is underway with major medical societies.

Springbok Analytics is an FDA-cleared medical device and software company specializing in advanced muscle health analytics derived from MRI imaging. The company develops AI-driven musculoskeletal analysis software that processes standard MRI scans to quantify individual muscle volume, fat infiltration, symmetry, and quality at pixel-level precision. Springbok serves three primary markets: (1) Research & Clinical Trials—accelerating muscle-related research with standardized, MRI-based quantification; (2) Elite Sports & Performance—tracking athlete muscle metrics for return-to-play and performance optimization (clients include NBA, NFL, Utah Jazz, DC United); and (3) Longevity & Preventive Health—objective tracking of muscle health over time for personalized health strategies. The platform analyzes over 100 individual muscles across legs, core, back, chest, shoulders, and arms, and can assess tendons, bone, scar tissue, and edema. Scans take 10–45 minutes to acquire; processing occurs within 24 hours, with detailed 3D visualizations and muscle-level data delivered via interactive web-based viewer within 2–3 days. The company is recognized for pioneering 3D musculoskeletal digital twin technology and was named a Fast Company Most Innovative Company in 2024. Regulatory clearance: FDA-cleared device.

Medicomp Systems is a clinical AI software company founded in 1978, specializing in evidence-based clinical intelligence solutions for healthcare providers and technology partners. The company's flagship Quippe suite delivers a clinically intelligent data platform built on the MEDCIN clinical knowledge foundation, transforming unstructured clinical data into actionable insights at the point of care. Quippe integrates with EHRs and health IT systems to improve documentation efficiency, clinical decision-making, coding accuracy, and care compliance. The platform features deterministic clinical reasoning engines, universal clinical data standardization, and extensive clinical knowledge graphs mapping diagnostic relationships across symptoms, patient history, physical exams, genomics, tests, medications, and treatments. Medicomp's solutions enable healthcare organizations and software developers to embed sophisticated clinical understanding into their systems while reducing documentation burden and improving clinician satisfaction. The company collaborates with leading medical institutions to continuously validate its clinical knowledge base, ensuring tools meet real-world provider and patient needs.

NotAlVision Inc. is a digital health company specializing in remote patient monitoring services for retinal diseases, particularly age-related macular degeneration (AMD). The company develops home-based diagnostic devices operated by patients and AI-enabled data analysis platforms to extend eye disease management from traditional clinic settings into patients' homes. NotAlVision's platform addresses the unmet diagnostic need in ophthalmology by enabling real-time, automated analysis of patient testing data through proprietary AI algorithms. The company's approach aims to improve treatment outcomes by facilitating treatment decisions that align with each patient's disease activity timing rather than pre-scheduled clinic appointments. Key clinical focus areas include early detection of dry AMD progression to wet AMD, improving real-world wet AMD treatment outcomes, and optimizing treatment timing to reduce under-treatment. The platform connects patients and physicians 24/7 through a monitoring center and includes a suite of patient-operated home-based diagnostic devices. NotAlVision targets ophthalmology practices and retinal specialists seeking to improve patient engagement, diagnostic accuracy, and clinical outcomes in AMD management. The company combines precision medicine principles with telehealth capabilities to address the acute onset and unpredictable nature of retinal disease progression.